Speciality enzyme company, Biocatalysts Ltd, has delivered the first customer product that was fermented and processed in its state-of-the-art enzyme manufacturing facility.
The unique enzyme was scaled up and commercialised in less than 10 months to meet the demands of the customers’ manufacturing schedule.
It is a testament to the team that the plant commissioning, validation, and production of the first commercial product was done during these unprecedented times and shows Biocatalysts Ltd.’s commitment to providing large-scale fermentation services.
To ensure a reliable and robust service the manufacturing facility has been designed to deliver a unique, fully automated ‘LEAN’ manufacturing process, ensuring maximum yield recovery at every stage of the process.
The extension is capable of E. coli, Pichia and Yarrowia fermentations and subsequent down-stream-processing. The new fermentation capacity increases its existing portfolio, extending its fermentation scales to 3L, 75L, 750L and 10,000L and has been designed to accommodate future growth.
The whole process is controlled by state-of-the-art Siemens software to maximise capacity and enhance efficiencies, guaranteeing world-class support and service.
Coupled with its award-winning enzyme discovery, development and manufacturing process Biocatalysts Ltd truly have a unique breadth of offering in the biotechnology marketplace.
Craig Galeozzie, Director of Operations at Biocatalysts Ltd, commented: “The strategic planning, design and subsequent installation has been an incredible 3-year journey, ultimately delivering a conceptual ‘LEAN’ process that provides us with a unique facility unrivalled in the industry.
“Built on the foundations of teamwork, the extension project is another example of the extraordinary commitment, professionalism and dedication of our staff to exceed our customers’ expectations as we further develop the facility and strengthen our marketability.”